Prestige Wealth Management Group’s Adaptive Biotechnologies ADPT Stock Holding History

Prestige Wealth Management Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25	Closed	-$374	–	1011
2025 Q3	$374	Hold	25	–	–	﹤0.01%	957
2025 Q2	$292	Hold	25	–	–	﹤0.01%	973
2025 Q1	$186	Hold	25	–	–	﹤0.01%	986
2024 Q4	$150	Hold	25	–	–	﹤0.01%	1024
2024 Q3	$128	Hold	25	–	–	﹤0.01%	1017
2024 Q2	$91	Hold	25	–	–	﹤0.01%	977
2024 Q1	$81	Hold	25	–	–	﹤0.01%	1012
2023 Q4	$123	Hold	25	–	–	﹤0.01%	1007
2023 Q3	$137	Hold	25	–	–	﹤0.01%	1035
2023 Q2	$168	Hold	25	–	–	﹤0.01%	1041
2023 Q1	$221	Hold	25	–	–	﹤0.01%	1032
2022 Q4	$191	Hold	25	–	–	﹤0.01%	1128
2022 Q3	$0	Hold	25	–	–	﹤0.01%	962
2022 Q2	$0	Sell	25 -67	-73%	-$589	﹤0.01%	966
2022 Q1	$1K	Hold	92	–	–	﹤0.01%	835
2021 Q4	$3K	Hold	92	–	–	﹤0.01%	708
2021 Q3	$3K	Hold	92	–	–	﹤0.01%	712
2021 Q2	$4K	Buy	92 +25	+37%	+$972	﹤0.01%	660
2021 Q1	$3K	Hold	67	–	–	﹤0.01%	704
2020 Q4	$4K	Sell	67 -2	-3%	-$103	﹤0.01%	608
2020 Q3	$3K	Hold	69	–	–	﹤0.01%	604
2020 Q2	$3K	Buy	69 +42	+156%	+$1.53K	﹤0.01%	587
2020 Q1	$1K	Buy	+27	New	+$753	﹤0.01%	704

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prestige Wealth Management Group's ADPT Position: Q4 2025 in Review

Prestige Wealth Management Group sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 25 shares — an estimated $374 sold.

Prestige Wealth Management Group first reported a position in ADPT in Q1 2020 and held it in 23 quarters. The position peaked at $4K in Q2 2021. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Prestige Wealth Management Group reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Prestige Wealth Management Group sold 25 Adaptive Biotechnologies shares in Q4 2025, an estimated $374.
Prestige Wealth Management Group first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 23 quarters.
Prestige Wealth Management Group's Adaptive Biotechnologies position peaked at $4K in Q2 2021.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Prestige Wealth Management Group's 13F filing for Q4 2025, filed 11 Feb 2026.